Radiopharma-focused Telix heats up IPO summer market with $200M offering

Australian radiopharmaceuticals biotech Telix Pharmaceuticals is targeting a $200 million initial public offering in the U.S.

The expected Nasdaq debut consists of 17,000,000 American depositary shares (ADSs), plus a 30-day option for underwriters to purchase up to 15% more ADSs sold in the offering at the initial price, according to a June 5 release.